期刊文献+

视网膜疾病基因治疗现状与前景 被引量:2

原文传递
导出
摘要 基因治疗是通过向靶细胞或组织中引入外源基因片段来纠正疾病状态。基因治疗依赖所采用的载体系统使外源基因编码的蛋白在靶组织中高效、稳定的表达。视网膜疾病基因治疗中较为常用的载体是重组腺相关病毒载体、腺病毒载体、慢病毒载体等病毒类载体。通过将外源目的基因与促进子包装于病毒衣壳后制成病毒载体,再将载体注射入眼内。但最终将视网膜疾病基因治疗应用于临床尚有许多关键问题需要解决,如基因表达产物的调控、基因转移靶向性的控制、合适基因载体的选择、载体及导人物质引起的免疫反应等。随着对视网膜疾病分子遗传机制了解的不断深入及新技术和载体的发展,视网膜疾病基因治疗必将成为现实。
出处 《中华眼底病杂志》 CAS CSCD 北大核心 2011年第5期494-496,共3页 Chinese Journal of Ocular Fundus Diseases
基金 国家自然科学基金(30973251)
  • 相关文献

参考文献29

  • 1Martin KR, Klein RL, Quigley HA. Gene delivery to the eye using adeno-associated viral vectors. Methods, 2002, 28: 267- 275.
  • 2Anderson WF. Human gene therapy. Science, 1992, 256,808- 813.
  • 3Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet, 2001, 28: 92-95.
  • 4Pechan P, Rubin H, Lukason M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther, 2009, 16: 10-16.
  • 5Liu MM, Tuo J, Chan CC. Gene therapy for ocular diseases. Br J Ophthalmol, 2011, 95:604-612.
  • 6Alloeca M, Mussolino C, Garcia-Hoyos M, et al. Novel adeno- associated virus serotypes efficiently transduce murine photoreceptors. J Virol, 2007, 81 : 11372-11380.
  • 7Liu J, Saghizadeh M, Tuli SS, et al. Different tropism of adenoviruses and adeno-associated viruses to corneal cells: implications for corneal gene therapy. Mol Vis, 2008, 14:2087- 2096.
  • 8Carter BJ. Adeno-associated virus and the development of adeno- associated virus vectors; a historical perspective. Mol Ther, 2004, 10:981-989.
  • 9Le Meur G, Weber M, Pereon Y. Postsurgical assessment and long-term safety of recombinant adeno-associated vlrus-mediated gene transfer into the retinas of dogs and primates, 2005, 123: 500-506.
  • 10Balaggan KS, Binley K, Esapa M, et al. Stable and efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors. J Gene Med, 2006, 8:275-285.

同被引文献39

  • 1杨培增.葡萄膜炎的研究进展[J].中华眼科杂志,2005,41(12):1149-1152. 被引量:39
  • 2Roth DB, Verma V, Realini T, et al. Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology ,2009,116:455-460.
  • 3Lau LI, Chen KC, Lee FL, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection in a Chinese population. Am J Ophthalmol,2008 ,146 :573-578.
  • 4Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet,2001,28 :92- 95.
  • 5Simonelli F, Maguire AM, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther, 2010,18 : 643 -650.
  • 6Campochiaro PA. Gene transfer for ocular neovascularization and macular edema. Gene Ther,2012,19 : 121-126.
  • 7Mancuso K, Hauswirth WW, Li Q, et al. Gene therapy for red-green colour blindness in adult primates. Nature.2009,461:784-787.
  • 8Ali RR. Ocular gene therapy:introduction to the special issue. Gene Ther ,2012,19 : 119-120.
  • 9Demir T, G,dekmerdan A, Balbaba M, et al. The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis. Indian J Ophthalmo1,2006,54:241-245.
  • 10De Kozak Y,Thillaye-Goldenberg B, Naud MC, et al. Inhibition of experimental autoimmune uveoretinitis by systemic and subconjunctival adenovirus-mediated transfer of the viral IL-10 gene. Clin Exp Immunol,2002,130:212-223.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部